HIV suppression not as good as previously thought, largest study of viral-load blood tests show

July 22, 2012, Johns Hopkins University School of Medicine

Tens of thousands of Americans taking potent antiretroviral therapies, or ART, to keep their HIV disease in check may not have as much control over the viral infection as previous estimates have suggested, according to results of a study by AIDS experts at Johns Hopkins and the University of Pennsylvania.

In what is believed to be the largest and longest review of viral load test results in people with HIV disease ever performed in the United States, researchers found that the number of people sustaining viral suppression – consistently, at 400 or less viral copies per milliliter of blood, year after year – is roughly 10 percent less than previous estimates. The team's findings are set to appear in the Journal of the American Medical Association online July 25. The publication is timed to coincide with the XIX International Conference in Washington, D.C.

According to senior study investigator and infectious disease specialist Kelly Gebo, M.D., M.P.H., the team's latest findings underscore just how difficult it is to successfully treat HIV disease and prevent its spread even when people are taking effective ART. Gebo says that "if we are not fully suppressing the virus as much as we thought, then we are not fully preventing and reducing the likelihood of HIV transmission, either." Some 426,000 of the estimated 1.2 million Americans infected with the virus that causes AIDS are taking ART and are under the routine care of a physician.

Gebo says that, overall, while ART has improved significantly within the last decade, with once-a-day pill regimens replacing more complicated, multidrug schedules, "our study findings suggest that physicians and other health care providers still need to do more to promote drug adherence among our patients, and make sure people take their as prescribed."

Without that extra effort, she says, "More people are potentially at risk of becoming infected with HIV, and those already on ART are at risk of developing drug resistance, too." Gebo is an associate professor at the Johns Hopkins University School of Medicine and the University's Bloomberg School of Public Health.

As part of the decade-long study, more than 100,000 individual blood test results were reviewed, all obtained with permission from the medical records of 32,483 infected adults. Seventy percent were men. Everyone prescribed ART had their blood viral levels carefully monitored at more than a dozen established HIV clinics, including the Moore Clinic at The Johns Hopkins Hospital.

Among the study's specific findings was that the percentage of participants who tightly controlled their HIV disease was 72 percent in 2010, the last year for which viral load counts were analyzed. This represented a major increase from 45 percent in 2001, but was significantly less than the 77 percent to 87 percent figures widely cited in 2011 reports from the U.S. Centers for Disease Control and Prevention, and in studies by other leading Hopkins and Canadian researchers.

According to study lead investigator Baligh Yehia, M.D., M.S.H.P., M.P.P., a postdoctoral fellow at the University of Pennsylvania School of Medicine in Philadelphia who trained as a medical resident at Johns Hopkins, all previous reports were based on single-year or one-time-only recordings of blood viral levels, rather than a review of every patient's individual from year to year. The latter, he says, is a "more accurate" depiction of people's response to ART over the long term.

Other key findings in the latest report were that younger people, ages 18 to 29; blacks; injection drug users; and those without private health insurance were almost twice as likely as older people; whites; men who have sex with men; and those with private insurance to not have fully suppressed blood viral levels.

"Our data shows that while tremendous strides have been made in sustaining , physicians and other HIV care providers need to be more vigilant in monitoring the viral loads in young people, African-Americans, injection drug users and those who lack health insurance," says Yehia.

Gebo and Yehia next plan to use their study data to develop programs for helping people with HIV adhere to therapy and keep routine appointments with their physicians. The team also has plans to interview infected people who consistently adhered to ART and medical care, and those who did not, to better understand the reasons behind successful and failed attempts to sustain and tightly control the disease.

Currently, there are more than 34 million people in the world living with , including an estimated 1,178,000 in the United States and 23,000 in the state of Maryland.

Explore further: Benefits of HIV drugs rise -- but less than previously believed, study shows

Related Stories

Benefits of HIV drugs rise -- but less than previously believed, study shows

July 22, 2012
The percentage of HIV patients taking antiretroviral drugs who experienced the full benefit of the drugs jumped from 45 percent of 72 percent during the past decade, a figure that is lower than previous estimates. The findings, ...

First guidelines issued for getting people newly diagnosed with HIV disease into care

March 5, 2012
Leading AIDS experts at Johns Hopkins and other institutions around the world have issued new guidelines to promote entry into and retention in HIV care, as well as adherence to HIV treatment, drawn from the results of 325 ...

Many Americans with HIV go untreated: study

November 29, 2011
Nearly three quarters of the 1.2 million Americans with HIV do not have their infection under control, raising the risk of death from AIDS and transmission to others, said a US study on Tuesday.

Vaccination strategy may hold key to ridding HIV infection from immune system

March 8, 2012
Using human immune system cells in the lab, AIDS experts at Johns Hopkins have figured out a way to kill off latent forms of HIV that hide in infected T cells long after antiretroviral therapy has successfully stalled viral ...

One in four U.S. HIV patients don't stay in care, study shows

March 6, 2012
(Medical Xpress) -- Only about 75 percent of HIV/AIDS patients in the United States remain in care consistently, according to new research from the Perelman School of Medicine at the University of Pennsylvania published online ...

Recommended for you

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.